ReCor Medical Announces Completion of Enrollment in RADIANCE-II Pivotal Trial
ReCor Medical notes the data from RADIANCE-II will build on evidence from RADIANCE-HTN SOLO and TRIO studies to support pre-market application to the FDA
March 29, 2022